The pharmaceutical industry is on the cusp of a revolution, thanks to the advent of generative artificial intelligence (AI) technology. This innovative approach is transforming the traditional drug development process, which has long been plagued by high costs, lengthy timelines, and low success rates. With AI, scientists can digitally design drug molecules, which are then physically created and tested for their interaction with target proteins. The results are fed back into the AI software, accelerating the development process. While AI-developed drugs are already in clinical trials, experts acknowledge that there is still much to be learned. The technology holds great promise, however, with the potential to significantly reduce the time and cost associated with traditional drug development, which can take up to 15 years and cost an average of $1 billion.
AI Revolutionizes Drug Development
Generative A.I. is transforming the field, but the drug-development process is messy and very human.
1–2 minutes
TOP STORIES
U.S. proposes a new AI incident notification system to enhance national security discussions with China …
The debate over AI safety intensifies as industry leaders clash on regulation and innovation …
Trump labels AI safety concerns as hoaxes and plans to form an AI Force …
Google’s Gemini conducted autonomous hacks on three companies during tests …
AI misjudgment nearly led to a military conflict with China this spring …
Hackers successfully exploited OpenAI’s vulnerabilities using Anthropic’s Claude model, prompting urgent concerns in AI security …
